DGAP-News: PAION AG: PAION AG ANNOUNCED RECRUITEMENT OF ONO'S HEPATIC IMPAIRMENT STUDY WITH REMIMAZOLAM (DEVELOPMENT CODES: ONO-2745/CNS 7056) IS COMPLETED
(firmenpresse) - DGAP-News: PAION AG / Key word(s): Research Update
PAION AG: PAION AG ANNOUNCED RECRUITEMENT OF ONO'S HEPATIC IMPAIRMENT
STUDY WITH REMIMAZOLAM (DEVELOPMENT CODES: ONO-2745/CNS 7056) IS
COMPLETED
30.10.2013 / 07:30
---------------------------------------------------------------------
PAION AG ANNOUNCED RECRUITEMENT OF ONO'S HEPATIC IMPAIRMENT STUDY WITH
REMIMAZOLAM (DEVELOPMENT CODES: ONO-2745/CNS 7056) IS COMPLETED
Aachen (Germany), 30 Oktober 2013 - PAION AG (ISIN DE000A0B65S3; Frankfurt
Stock Exchange General Standard: PA8) today announced that its Japanese
development partner, Ono Pharmaceutical Co., Ltd. ('Ono') has completed the
recruitment of a study in patients with chronic hepatic impairment using
Remimazolam (development codes: ONO-2745/CNS 7056). This was the study
required to complete the Japanese development program for the indication of
induction and maintenance of general anesthesia.
This study was conducted in the USA as an open-label study with sequential
parts to compare the pharmacokinetics and safety of Remimazolam in subjects
with chronic hepatic impairment with their respectively matching healthy
volunteers.
No adverse events of concern were observed in this study.
ONO entered into a license agreement with PAION in August 2007, acquiring
the exclusive rights to develop and market Remimazolam in Japan.
Dr. Mariola Söhngen, the Chief Medical Officer at PAION states: 'Once again
we can congratulate our partner ONO. After completion of the Japanese
development work for the indication of induction and maintenance of general
anesthesia we look forward to the study results of the Phase III program
and to PMDA filing.'
###
About PAION
PAION AG is a publicly-listed biotech company headquartered in Aachen,
Germany with a second site in Cambridge, UK. The company has a track record
in developing hospital-based treatments for which there is substantial
unmet medical need. PAION AG is transforming its business model from a pure
development company to a specialty pharmaceutical company with a focus on
anaesthesia products to take advantage of the unique profile of its main
compound, Remimazolam.
About Remimazolam
Remimazolam is an innovative short-acting general anaesthetic/sedative. Due
to its short duration of action and good controllability, it has a
favorable efficacy and safety profile relative to other currently marketed
anaesthesia compounds. The rapid offset of Remimazolam's effect is due to
its metabolism by tissue esterase enzymes that are widely distributed
throughout the body.
Remimazolam has potential in three indications:
- Procedural sedation
- General anaesthesia
- ICU sedation
Remimazolam is available for licensing outside Japan, China and South
Korea, where the compound is partnered with Ono Pharmaceutical, Yichang
Humanwell and Hana Pharm.
Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner(at)paion.com
www.paion.com
Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.
End of Corporate News
---------------------------------------------------------------------
30.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info(at)paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulierter Markt in Frankfurt (General Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
236644 30.10.2013
Themen in dieser Pressemitteilung:
paion-ag-paion-ag-announced-recruitement-of-ono-s-hepatic-impairment-study-with-remimazolam-development-codes-ono
2745-cns-7056-is-completed
Unternehmensinformation / Kurzprofil:
Datum: 30.10.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 310626
Anzahl Zeichen: 6539
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 286 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: PAION AG: PAION AG ANNOUNCED RECRUITEMENT OF ONO'S HEPATIC IMPAIRMENT STUDY WITH REMIMAZOLAM (DEVELOPMENT CODES: ONO-2745/CNS 7056) IS COMPLETED"
steht unter der journalistisch-redaktionellen Verantwortung von
PAION AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
